FDAAA’s First Advertising Victim Is MedImmune’s FluMist
This article was originally published in The Pink Sheet Daily
“Reminder” newspaper ad actually makes claims and lacks toll-free number for reporting side effects, FDA says.
You may also be interested in...
Industry will have an extra six months - until July 1, 2009 - to comply with a requirement that drugs be dispensed with information on a toll-free number for reporting adverse events, according to a final rule on the topic issued by FDA Oct. 28
Agency issues an "untitled" letter to Takeda citing the 10-second TV spot.
Independent review panel will be established to handle complaints about pharmaceutical advertising.